Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 13/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258630 | 0.85 | CYP1A2 (0.46) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24444132 | 0.85 | CYP1A2 (0.46) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL21263864 | 0.84 | SLC29A1 (0.56) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24258662 | 0.83 | SLC29A1 (0.40) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24258589 | 0.83 | SLC29A1 (0.39) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL25688724 | 0.79 | SLC29A1 (0.49) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL7027953 | 0.76 | SLC29A1 (0.58) | SLC29A1POLA1CYP3A4LMNARAB9A | |
| SCHEMBL29471805 | 0.74 | LMNA (0.51) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL21263857 | 0.74 | LMNA (0.41) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL25688725 | 0.73 | SLC29A1 (0.39) | SLC29A1CYP3A4LMNARAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | SLC29A1 537/4885POLA1 63/4885CYP3A4 3633/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | SLC29A1 537/4885POLA1 63/4885CYP3A4 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.